Mayo Clinic

Mayo Clinic research at ObesityWeek 2024 demonstrates precision medicine's role in transforming obesity prevention. MENLO PARK, Calif., Nov. 14, 2024 /PRNewswire/ -- Phenomix Sciences, a precision medicine biotechnology company that brings data intelligence to obesity treatment, announces today the findings from new research conducted at Mayo Clinic and presented at ObesityWeek 2024. For the first time, this early data demonstrates the utility of the MyPhenome test in predicting future weight gain, a key area of obesity care. The study showed participants with abnormal satiation and high gene risk scores experienced 4% greater weight gain after five years. The study, Gene Risk Score for Satiation Is Associated with Prospective Weight Gain, was presented by Diego Anazco, M.D., research fellow at Mayo Clinic. Over a five-year period, 71 participants with high gene risk scores (GRS) for abnormal satiation as identified by the MyPhenome test gained more weight (8.5% ± 1.6) than those with a low GRS (4.7% ± 1.3 p<0.05). These findings suggest the MyPhenome test's utility in identifying individuals at risk of progressive weight gain and highlighting a need for a targeted early intervention approach in obesity. "With the continued groundbreaking research from our founders Dr. Acosta and Dr. Camilleri, we know more about the genetics of obesity than ever before," said Mark Bagnall, CEO of Phenomix Sciences. "For the first time, our company is looking beyond weight loss, and helping guide the industry toward early intervention and obesity screening. This approach has the potential to deliver significant economic and clinical benefits. These findings highlight the significant impact precision medicine is having in obesity treatment and we look forward to supporting continued research in this space." A previous study presented at Digestive Disease Week 2024 demonstrated the clinical utility of the MyPhenome test to predict response to semaglutide and reduce variability in response to this weight loss medication for patients without pre-diabetes or Type 2 diabetes. Led by Andres Acosta, M.D., Ph.D., associate professor at Mayo Clinic and co-founder of Phenomix Sciences, studies have also shown obesity treatments tailored to patients' biological traits and identified through the MyPhenome test are twice as effective as other one-size-fits-all treatments. Visit myphenometest.com to order the MyPhenome test or find a clinic offering the test near you. To find out more about Phenomix Sciences and supporting research, click here. About Phenomix Sciences Phenomix Sciences is a precision obesity biotechnology company on a mission to conquer obesity globally through the use of our proprietary genetic tests, unique data sets and advanced analytics. Phenomix believes that the key to understanding obesity is its unprecedented access to clinical and molecular information throughout all stages and phenotypes of the disease. Phenomix leverages data intelligence to yield better accuracy in predicting individual patient response to specific weight loss interventions and reducing the variability in weight loss results for patients. For more information, please visit . Media Contact: [email protected] SOURCE Phenomix Sciences WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

CAMBRIDGE, Mass.--( BUSINESS WIRE )-- Anumana , a leading AI-driven health technology company, will showcase its leadership in AI-powered cardiovascular solutions at the American Heart Association (AHA) Scientific Sessions 2024 , booth #708, in Chicago, and at the North American Primary Care Research Group (NAPCRG) Annual Meeting in Quebec City. “Empowering physicians with real-time, clinically meaningful insights is at the heart of Anumana’s mission,” said Maulik Nanavaty, CEO of Anumana. “We look forward to showcasing our ECG-AI algorithm, which uses a standard 12-lead ECG to detect low ejection fraction—a key indicator of heart failure. By transforming routine tests into tools that enable earlier diagnosis and treatment, we aim to elevate standards in cardiovascular care and improve patient outcomes.” At the conferences, Anumana will feature its FDA-cleared ECG-AI™ Low Ejection Fraction (LEF) algorithm, which is currently available in the U.S. and was recently recognized in the CMS 2025 OPPS final rule. The company will also host expert panel discussions to highlight the role of AI in clinical care. AHA Scientific Sessions Panel session: “ The Future of AI in Cardiology: Trends, Expert Insights, and Panel Discussion ” November 17 at 12:30 p.m. CT The session will explore the latest trends of AI/ML devices in cardiology, highlighting the journey of ECG-AI LEF from its initial concept to becoming an FDA-cleared Software as a Medical Device (SaMD). Experts will discuss the opportunities, challenges, and solutions shaping the future of AI in cardiology. Speakers: Samir Awasthi, MD, PhD; Heather Alger, PhD; Ambarish Pandey, MD; Mark Stampehl, MD Abstract presentation: “ Deep Learning Enabled Electrocardiogram Aimed to Detect Coronary Artery Disease to Predict Atherosclerotic Cardiovascular Events in the Community ” Presentation: November 16 at 10:20-10:25 a.m. CT Speaker: Jose R Medina-Inojosa, MD, MSc “Equity in Equations” Breakfast Symposium: November 17 at 6:30-8:00 a.m. CT NAPCRG Annual Meeting Workshop topic: “ Primary Care is the Next Frontier for AI Disruption: Low EF ECG-AI Algorithm Development as a Case Study ” November 21 at 1:45-3:15 p.m. ET The 90-minute workshop will feature experts who will explore how AI innovations can be integrated into primary care workflows. Topics will cover recent advancements in health technology tools tailored for clinical care, the current state of AI-powered ECG tools, and essential considerations for evaluating and selecting health technology tools for primary care. Speakers: Heather Alger, PhD, MPH; Rowena Dolor, MD, MHS, MHS; David Rushlow, MD, MBOE; Chris Pullins, MD Anumana’s ECG-AI platform includes a suite of algorithms designed to help clinicians detect cardiovascular diseases using ECG data. In addition to its FDA-cleared ECG-AI LEF algorithm, Anumana has also received FDA Breakthrough Device Designation for its pulmonary hypertension , cardiac amyloidosis , and hyperkalemia algorithms. The company’s AI tools unlock critical insights from ECGs to enhance the detection and management of heart disease. About Anumana Anumana is a leading AI-driven health technology company leveraging cutting-edge AI and industry-leading translational science to unlock the electrical language of the heart as never before. The company was founded by nference in collaboration with Mayo Clinic to leverage the clinical and technical expertise of both organizations to develop innovative ECG-AI technology into a clinically meaningful, medical-grade, and easy-to-use tool for clinicians to advance patient care. Anumana’s software-as-a-medical device (SaMD) ECG-AI™ solutions aim to detect diseases earlier using standard-of-care ECG readings, enabling clinicians to enhance and improve care with real-time AI insights. Anumana’s award-winning lead algorithm, ECG-AI™ LEF, is now available in the U.S. To learn more about how the algorithm can help clinicians identify LEF earlier and schedule a demo, visit us at ECG-AI LEF . For more information, visit www.anumana.ai or follow us on LinkedIn and X .

Code paves the way for reimbursement and expanded clinical use of AI-enabled heart disease detection SAN FRANCISCO, Nov. 14, 2024 /PRNewswire/ -- Eko Health, a pioneer in applying artificial intelligence for early detection of heart and lung diseases, today announced the issuance of a Category III Current Procedural Terminology (CPT) code by the American Medical Association (AMA) for its SENSORA™ platform. The newly issued Category III CPT code will be effective on July 1, 2025, and is the first step to coverage and reimbursement for SENSORA™, bringing advanced heart disease detection to clinicians across the U.S. Continue Reading Code paves the way for reimbursement and expanded clinical use of AI-enabled heart disease detection. SENSORA is an advanced early disease detection platform that includes FDA-cleared AI algorithms that identify signs of structural heart murmurs, low ejection fraction (Low EF), and arrhythmias, including AFib, in the front-line care setting. It seamlessly integrates with Eko's CORE 500™ digital stethoscope, which embeds advanced ECG technology in a tool that every provider is familiar with. Heart disease remains the leading cause of death in the United States, accounting for about 1 in every 5 deaths, according to the CDC. Early detection plays a critical role in improving patient outcomes. By empowering primary care providers to identify cardiac issues earlier, SENSORA™ enhances proactive care and reduces the burden of advanced heart disease management. "The AMA's creation of Category III CPT code for Eko's AI disease detection algorithms is a major step in increasing access to early heart disease detection," said Connor Landgraf, CEO of Eko Health. "This milestone will help enable clinicians to use powerful, validated tools to identify heart disease early, ultimately improving patient outcomes, especially in communities with limited access to specialist care." SENSORA's AI algorithms, validated in clinical and real-world studies, assist clinicians in detecting cardiac disease signs often missed by standard care. An independent clinical validation published in Circulation showed that Eko's structural heart murmur detection AI doubled sensitivity for structural heart disease compared to an analog stethoscope. Additionally, a Lancet Digital Health study involving over 1,000 patients confirmed Eko's low ejection fraction AI accurately detects reduced ejection fraction in primary care, leading to its deployment in over 100 UK clinics by the NHS and Imperial College London. The Category III CPT code reflects SENSORA's growing role as an essential tool in cardiac care and is expected to expand its use across multiple clinical environments. This designation is a testament to Eko's commitment to equipping primary care clinicians with AI tools that elevate patient care standards and bridge the preventive care gap. About Eko Health Eko Health is a leading digital health company advancing how healthcare professionals detect and monitor heart and lung disease with its portfolio of digital stethoscopes, patient and provider software, and AI-powered analysis. Its FDA-cleared platform, used by over 500,000 healthcare professionals worldwide, allows them to detect earlier and with higher accuracy, diagnose with more confidence, manage treatment effectively, and ultimately give their patients the best care possible. Eko Health is headquartered in Emeryville, California, with over $165 million in funding from ARTIS Ventures, DigiTx Partners, Double Point Ventures, EDBI, Highland Capital Partners, LG Technology Ventures, Mayo Clinic, Morningside Technology Ventures Limited, NTTVC, Questa Capital, and others. For more information, visit . Media Contact Sam Moore [email protected] SOURCE Eko Health WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED